Last reviewed · How we verify
NCT04627350: ELEGANCE
Early Detection of Lung Cancer in Czech High-risk Asymptomatic Individuals
trial testing Response to pulmonary finding (nodule, mass) in Lung Cancer in 3,200 participants. Status unknown.
31 December 2023
Quick facts
| Lead sponsor | Charles University, Czech Republic |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 3,200 |
| Start date | 1 August 2020 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across Czechia |
Drugs / interventions tested
- Response to pulmonary finding (nodule, mass)
Conditions studied
- Lung Cancer — all drugs for Lung Cancer →
Sponsor
Charles University, Czech Republic
Who can join
Adults 55 to 74, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to evaluate and optimize entry criteria for the proposed programme for early detection of lung cancer in the Czech Republic. An estimated 3200 high-risk (age 55-74 years, \>30 pack-years) asymptomatic individuals will undergo baseline low-dose chest CT (LDCT) and a follow-up LDCT at 1 year. Patients with poor performance status (PS) 2-4, history of malignancy in the past 10 years, chest CT in the past 1 year, bodyweight \>140kg will not be included. The patients will fill out a questionnaire with basic data, including smoking history (pack-years), history of previous malignancy, CT imaging of the thorax, and will undergo spirometry. Outcomes of the study include: * optimization of entry criteria, optimization of timing of a follow-up LDCT and management of the patients, proposal of quality assurance indicators * influence of screening on the stage of lung cancer at the time of the diagnosis and life-years lost * cost-effectiveness of the screening program * evaluation of the diagnostic yield for secondary findings (pulmonary fibrosis, cardiovascular risk)
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Early detection of lung cancer in Czech high-risk asymptomatic individuals (ELEGANCE): A study protocol.
Lambert L, Janouskova L, Novak M, Bircakova B, et al · · 2021 · cited 4× · PMID 33592843 · DOI 10.1097/md.0000000000023878
Verify or expand the search:
- PubMed search for NCT04627350
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Cancer
Currently open trials in the same condition.
- NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
- NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
- NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting
Other Charles University, Czech Republic trials
Trials by the same sponsor.
- NCT07475481 — Exercise-Based Strategies for Chronic Back Pain · NA · not yet recruiting
- NCT07468318 — Multimodal Therapy for Somatosensory Tinnitus · NA · not yet recruiting
- NCT07525154 — Development of a Certified Testing Procedure for Hip and Groin Injuries in Athletes · NA · not yet recruiting
- NCT07512570 — Feasibility and Preliminary Effects of a Structured Resistance Training Program in Children Aged 10-14 Years · NA · not yet recruiting
- NCT07424326 — Extended Ablation Versus Pulmonary Vein Isolation to Treat Persistent Atrial Fibrillation · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04627350 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Charles University, Czech Republic
- Last refreshed: 13 November 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04627350.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing